Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
10.12.2020 16:00:00 EET | Business Wire | Press release
Boehringer Ingelheim today announced the signing of a binding agreement for acquiring all shares of NBE-Therapeutics, a private, clinical-stage Swiss biotechnology company focused on antibody-drug conjugates and advancing targeted cancer therapies derived from its immune stimulatory iADC™ platform. NBE-Therapeutics’ lead compound NBE-002 is currently in phase I clinical studies for triple negative breast cancer and other solid tumors. Importantly, Boehringer Ingelheim gains access to an innovative and unique platform that it will use to build a leading ADC portfolio and develop potential combinations with other assets from its cancer immunology portfolio.
“NBE-Therapeutics’ iADC platform adds exceptional tumor targeting capabilities to our oncology portfolio. Together with our immune cell-targeting assets, this could enable new powerful combinations that will allow for efficacious and durable treatments for patients,” said Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors with responsibility for the company’s Innovation Unit. “This acquisition is a further example of Boehringer Ingelheim’s long-term strategy to enhance our position as an innovator of novel cancer therapies for patients in need. We welcome NBE-Therapeutics’ richly talented team to Boehringer Ingelheim and we look forward to collaborating with them on this important work.”
The total transaction value is 1.18 billion euros and also includes contingent clinical and regulatory milestones.
“I am extremely proud of the NBE-Therapeutics’ team and delighted that our world class ADC expertise is being recognized by Boehringer Ingelheim. This transaction is a validation of our platform and its potential for the next generation cancer therapies,” said Bertrand Damour, Chief Executive Officer of NBE-Therapeutics. “We look forward to progressing NBE-002, our lead program and best-in-class anti ROR1 ADC, and to continuing the fight against cancer alongside Boehringer Ingelheim with its strong clinical development capabilities.”
Boehringer Ingelheim’s cancer cell directed research is focused on the development of targeted therapies for the treatment of difficult-to-treat solid tumors. Inducing tumor cell death is a key component, and ADC based approaches have emerged as a powerful targeted therapy with potential for induction of immunogenic cell death at reduced systemic exposure and toxicity.
The NBE-Therapeutics’ acquisition will significantly strengthen Boehringer Ingelheim’s strategic focus on targeted cancer cell-directed therapies and complements existing capabilities in antigen discovery as well as antibody and T-cell engager technologies. By combining its world-class, in-house research and development with that of highly innovative biotechnology companies, Boehringer Ingelheim is developing innovative therapies and accelerating the delivery of the next generation of cancer treatments. This builds on recent strategic acquisitions and collaborations, including the acquisition of ViraTherapeutics and AMAL Therapeutics, which are also contributing assets.
NBE-Therapeutics is headquartered in Basel, Switzerland, where it was founded with financial backing from a syndicate of both corporate and institutional investors, including the Boehringer Ingelheim Venture Fund, and PPF Group, as their largest shareholders, and Denmark’s Novo Holdings. NBE-Therapeutics’ technology platform and derived assets are protected by a broad portfolio of patents and licenses.
The consummation of the transaction is subject to customary closing conditions and is expected during the course of Q1 2021.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/agreement-acquire-nbe-therapeutics
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005538/en/
Contact information
NBE-Therapeutics
Bertrand Damour, CEO
E: bertrand.damour@NBE-Therapeutics.com
NBE-Therapeutics media enquiries:
Optimum Strategic Communications
Mary Clark, Manel Mateus, Elakiya Rangarajah
T: +44 (0) 20 3922 0900
E: NBE-Therapeutics@optimumcomms.com
Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
press@boehringer-ingelheim.com
Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: + 203-791-6672
press@boehringer-ingelheim.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Introducing Ledger Atom™—Everything You Value, Finally Secure15.10.2026 15:45:00 EEST | Press release
Ledger™, the global leader in secure infrastructure for digital ownership, today unveiled Ledger Atom™, a security and privacy device that runs your everyday apps, purpose-built to help protect your money, your AI agent approvals, and your privacy. The innovative architecture of Ledger Atom, leveraging Android™ open source alongside Ledger OS™, Ledger’s proprietary security-first operating system running on a secure element chip, allows you to approve sensitive actions in a secure environment while using all your everyday apps on a single device. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015445765/en/ Ledger has launched Ledger Atom, a security and privacy device that runs your everyday apps, purpose-built to help protect your money, your AI agent approvals, and your privacy. Your phone is not secure, and threats targeting it are escalating; mobile zero-days nearly doubled year over year in 2025, and commercial spywa
Meet Yuvo - The All-In-One Platform Helping Travel Brands Optimize Every Stage of Their Customer's Journey15.10.2026 15:36:00 EEST | Press release
Yuvo data shows that flight disruption hit more than 913 million passengers in 2025, and travellers are now buying travel protection at six times the pre-pandemic rate. Yet for most travel brands, a delayed flight still means support calls, refunds and lost customers. Yuvo turns those moments, and every other step of the trip, into revenue and loyalty. Most travel brands earn from their customers only once: when they book. Yuvo changes that. It helps partners earn across the whole journey, with no technology to build and full control of the customer relationship. Yuvo works with some of the biggest names in travel, turning the customer relationships they already have into an ongoing revenue stream while keeping them fully in control. Built by a team of seasoned travel tech experts, the platform has already helped more than 26 million travelers through its services, improving customer experience and building loyalty worldwide. Yuvo’s Services - adding value at every stage of the journey
TreviPay Named a Leader in Two 2026 IDC MarketScape Assessments for AI-Enabled A/R Automation and Embedded Payments15.10.2026 15:00:00 EEST | Press release
TreviPay, a global B2B payments infrastructure partner, today announced it has been named a Leader in two 2026 IDC MarketScape assessments: the IDC MarketScape: Worldwide AI-Enabled Accounts Receivable Automation Applications for the Enterprise 2026 Vendor Assessment and the IDC MarketScape: Worldwide Embedded Payment Applications in Accounts Receivable Workflows 2026 Vendor Assessment. The recognition comes as enterprise finance teams look beyond automating individual A/R tasks toward coordinating the decisions and actions that drive growth and improve cash flow. We believe these assessments reflect a market in which payment execution, cash application, credit, collections and customer experience are valued when working together in one connected system. The IDC MarketScape for Worldwide AI-Enabled Accounts Receivable Automation Applications for the Enterprise noted the following strengths: Flexible risk retention options: A partnership with Mastercard lets clients offer net terms with
Visa Direct Launches Stablecoin-Powered Money Movement as Pilots Move to Production15.10.2026 15:00:00 EEST | Press release
Today, Visa (NYSE: V) announced the next phase of its stablecoin strategy as Visa Direct stablecoin capabilities advance from pilot stage to commercial deployment. The milestone marks an important step in bringing stablecoin-enabled money movement into real-world commercial operations. In the initial rollout, Inyo Global, a Visa Direct processor, is the first enabler of this new offering, powering it for eligible Visa Direct clients and partners1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015116414/en/ Over the past year, Visa Direct has worked with clients and partners to explore how stablecoins can help improve the way businesses fund and move money across borders. As interest in faster, more flexible just-in-time funding solutions continues to grow, Visa is now seeing those efforts move beyond experimentation and into day-to-day business operations. As part of this next phase, Visa is working with Inyo Global, a p
Philip Morris International Announces EU Economic Footprint Study 2021-2025: Transformation Made in Europe15.10.2026 14:42:00 EEST | Press release
At a defining moment for Europe’s competitiveness, Philip Morris International Inc. (PMI) (NYSE: PM) today publishes the second edition of its EU Economic Footprint Study, prepared by EY-Parthenon. Spanning 2021 to 2025, the study demonstrates the scale of PMI’s contribution across the European Union and the capabilities developed through its transformation. The company’s footprint reaches far beyond its own operations, supporting suppliers, manufacturers, researchers, retailers, farmers, employees, and communities across Europe. Five key figures from the EU Economic Footprint Study 2021-2025: Nearly €343 billion in total contribution to the EU economy between 2021 and 2025. €22.3 billion in spending with European suppliers and €27.4 billion invested across PMI's European operations, strengthening industrial capacity and supply-chain resilience. €39.5 billion in exports, reinforcing Europe’s position as a manufacturing and export hub. Around 164,000 jobs supported in 2025, including ne
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom